A Pan-European Register-Based Observational Study of Abrocitinib and Conventional Systemic Therapies in Moderate and Severe Atopic Dermatitis: The DREAM TO TREAT AD Study Protocol

    April 2025 in “ Skin Health and Disease ”
    Elizaveta Gribaleva, Niels Steen Krogh, David Prieto-Merino, Bolaji Coker, Abaigeal Jackson, Ahmet Akkoç, Thomas Birkner, Erwin Bruninx, Con Hennessy, K.T. Chan, Lara Cutlar, Brian B. Farrell, G. Fletcher, Louise A. A. Gerbens, Anne Grete Frostrup, Dan Henrohn, Ariënna Hyseni, Alan D. Irvine, Rayka Malek, Claire McCarthy, Ida Vittrup, Wouter Ouwerkerk, Rowena Randall, Phyllis I. Spuls, Simon Francis Thomsen, Dmitri Wall, Stephan Weidinger, Thomas Werfel, Jochen Schmitt, Carsten Flohr
    TLDR Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
    The DREAM TO TREAT AD study is a pan-European observational study that aims to collect real-world data on the use of abrocitinib, a Janus kinase 1 inhibitor, and conventional systemic therapies in patients with moderate-to-severe atopic dermatitis. Conducted across five European registers, the study will run from 2023 to 2026 and focuses on treatment patterns, effectiveness, and patient outcomes. It uses a federated data analysis approach with DataSHIELD to ensure patient privacy while allowing centralized statistical analysis. The study's primary objective is to detail patient demographics, comorbidities, and disease severity at treatment initiation, with secondary objectives including characterizing treatment journeys and assessing changes in disease severity and patient-reported outcomes. This research will provide insights into the real-world effectiveness of systemic therapies for AD and demonstrate the feasibility of collaborative data analysis across multiple registers.
    Discuss this study in the Community →